Cardiovascular · PANCE / PANRE
Hyperlipidemia
Elevated LDL or triglycerides; statin therapy stratified by ACC/AHA risk groups.
Also known as: dyslipidemia, hypercholesterolemia, high cholesterol, LDL, statin
Overview
Elevated serum lipid levels — total cholesterol, LDL, or triglycerides — or low HDL. Primary modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Severe hypertriglyceridemia (TG ≥500 mg/dL) carries a distinct risk of acute pancreatitis.
🔒 Free preview limit reached
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Hyperlipidemia outline — plus all 514 diagnoses, 5,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Free to start · No credit card · Cancel anytime
Risk factors
- Primary (genetic):
- • Familial hypercholesterolemia (FH) — most common autosomal dominant disorder; LDL often >190; tendinous xanthomas, premature ASCVD
- • Familial combined hyperlipidemia, dysbetalipoproteinemia
- Secondary causes:
- • Hypothyroidism (always check TSH before starting statin)
- • Nephrotic syndrome
- • Cholestatic liver disease
- • Uncontrolled diabetes (both LDL and TG)
- • Alcohol use (TG ↑↑)
- • Medications: thiazides, beta-blockers, atypical antipsychotics, protease inhibitors, oral estrogens
Pathophysiology
LDL particles infiltrate the arterial intima, where they undergo oxidation. Oxidized LDL is engulfed by macrophages → foam cells → fatty streaks → atherosclerotic plaque. Plaque progression narrows the lumen (stable angina) or destabilizes and ruptures (acute coronary syndrome). High TG ≥500 directly causes pancreatic ductal injury via free-fatty-acid release and chylomicronemia.
Clinical presentation
Symptoms
- Almost always asymptomatic until ASCVD complication develops
- Tendinous xanthomas, xanthelasma, corneal arcus (especially premature) — physical signs of severe / familial forms
- Eruptive xanthomas on extensor surfaces — suggest TG >1000
- Lipemic serum (milky appearance) when TG very high
Signs / physical exam
- Xanthelasma (lipid deposits on eyelids)
- Corneal arcus before age 45 — suspect FH
- Tendinous xanthomas (Achilles, knuckle extensors) — FH
- Acanthosis nigricans suggests metabolic syndrome
Differential diagnosis
- Familial hypercholesterolemia (FH) — Autosomal dominant LDL >190, tendinous xanthomas, premature ASCVD family history (<55 men / <65 women); cascade screen first-degree relatives
- Hypothyroidism — LDL can rise markedly and fully reverses with levothyroxine; always check TSH BEFORE starting a statin
- Nephrotic syndrome — Heavy proteinuria, hypoalbuminemia, edema; treat underlying glomerular disease
- Cholestatic liver disease (primary biliary cholangitis) — Elevated alkaline phosphatase, pruritus, anti-mitochondrial antibody positive
- Uncontrolled diabetes mellitus — Mixed dyslipidemia (↑ TG, ↓ HDL, small dense LDL); improves with glycemic control
- Alcohol use disorder — Predominantly hypertriglyceridemia; counsel reduction or cessation
- Medication-induced — Thiazide diuretics, atypical antipsychotics, oral estrogens, protease inhibitors, beta-blockers (mild ↑TG, ↓HDL), corticosteroids
- Anorexia nervosa — Paradoxical elevation of cholesterol in severe restrictive eating; weight restoration normalizes
Diagnostic workup
Labs
- Fasting lipid panel (10-12 h fast): total cholesterol, HDL, triglycerides, calculated LDL
- Non-fasting acceptable for screening (per most current guidelines) — fasting required if TG >400 or for accurate LDL calculation
- TSH (rule out hypothyroidism), A1c, BMP, LFTs (baseline before statin)
- ApoB or Lp(a) in selected patients (FH, recurrent ASCVD on therapy)
- Calculate 10-year ASCVD risk (Pooled Cohort Equation) for patients 40-75 without ASCVD or DM
Diagnostic algorithm
| Group | Population | Recommended Therapy |
|---|---|---|
| 1 | Clinical ASCVD (MI, stroke, PAD, revascularization) | HIGH-intensity statin (atorvastatin 40-80 / rosuvastatin 20-40) |
| 2 | LDL ≥190 (untreated) | HIGH-intensity statin |
| 3 | Diabetes, age 40-75, LDL 70-189 | MODERATE-intensity (HIGH if multiple risk factors or 10-yr ASCVD risk ≥20%) |
| 4 | Primary prevention, age 40-75, 10-yr ASCVD risk ≥7.5% | MODERATE-to-HIGH intensity statin |
| — | 10-yr risk 5-7.5% (borderline) | Consider statin with risk enhancers (FH+, CKD, CAC scoring, Lp(a) elevated) |
| — | LDL goal not met on max statin | Add ezetimibe → PCSK9 inhibitor (high-risk ASCVD) |
Treatment
First-line
- Lifestyle: Mediterranean/DASH diet, reduced saturated fat (<6% calories), eliminate trans fat, exercise, weight loss, smoking cessation
- Statin therapy based on ACC/AHA 4 statin benefit groups:
- • Group 1 (Secondary prevention): clinical ASCVD — MI, stable angina, stroke, TIA, PAD, revascularization → HIGH-intensity statin
- • Group 2 (Severe primary hyperlipidemia): LDL ≥190 → HIGH-intensity statin
- • Group 3 (Diabetes): age 40-75 with diabetes → MODERATE-intensity (HIGH if multiple risk factors or ASCVD risk ≥20%)
- • Group 4 (Primary prevention): age 40-75 without DM, LDL 70-189, 10-yr ASCVD risk ≥7.5% → MODERATE-to-HIGH intensity (shared decision-making 5-7.5%)
- High-intensity statins: atorvastatin 40-80, rosuvastatin 20-40 (≥50% LDL reduction)
- Moderate-intensity: atorvastatin 10-20, rosuvastatin 5-10, simvastatin 20-40, pravastatin 40-80 (~30-49% reduction)
Second-line / adjunct
- Add-on therapies if LDL goal not met or statin-intolerant:
- • Ezetimibe — first add-on, ~15-20% additional LDL drop
- • PCSK9 inhibitors (evolocumab, alirocumab) — high-risk ASCVD or FH on max statin + ezetimibe
- • Inclisiran (siRNA against PCSK9) — twice-yearly injection
- • Bempedoic acid — statin-intolerant patients
- TG-targeted therapy (TG ≥500 to prevent pancreatitis; TG 150-500 secondary after LDL goal met):
- • Fibrates (fenofibrate preferred over gemfibrozil for combination with statin)
- • High-dose omega-3 fatty acids (icosapent ethyl — REDUCE-IT trial showed CV benefit)
- • Niacin — rarely used due to side effects (flushing, hepatotoxicity, glycemia)
Complications
- Atherosclerotic cardiovascular disease (MI, stroke, PAD)
- Acute pancreatitis (TG ≥500-1000)
- Statin-associated muscle symptoms (mild myalgia common; true rhabdomyolysis rare)
- Hepatotoxicity (mild ALT elevation common, hepatitis rare)
- New-onset diabetes (small absolute risk increase, outweighed by CV benefit in most)
PANCE pearls
- Check baseline LFTs and CK before starting a statin; routine surveillance LFTs are NO LONGER recommended unless symptomatic.
- Statin myopathy: check CK if muscle symptoms; stop if CK >10× ULN or symptoms severe. Many patients tolerate a lower-intensity or different statin on re-challenge.
- Drug interactions: statins metabolized by CYP3A4 (simvastatin, atorvastatin, lovastatin) interact with macrolides, azoles, amiodarone, grapefruit juice → ↑ rhabdo risk. Pravastatin and rosuvastatin avoid this pathway.
- Lipoprotein(a) — genetically determined, not modified by lifestyle. Elevated Lp(a) is independent ASCVD risk; PCSK9 inhibitors lower it ~25%.
- Familial hypercholesterolemia: cascade screen first-degree relatives. Early aggressive treatment (high-intensity statin starting in childhood/adolescence for affected family members) prevents premature ASCVD.
References
- AHA/ACC 2018 — 2018 AHA/ACC Guideline on the Management of Blood Cholesterol (Grundy et al., Circulation 2019)
- FOURIER — Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (Sabatine et al., NEJM 2017)
- ODYSSEY OUTCOMES — Alirocumab and Cardiovascular Outcomes after ACS (Schwartz et al., NEJM 2018)
- REDUCE-IT — Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia (Bhatt et al., NEJM 2019)
- Pooled Cohort Equations — 2013 ACC/AHA ASCVD Risk Calculator (Goff et al., Circulation 2014)
Practice Cardiovascular questions on FirstPassPA
Turn this outline into retention. 5,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Start studying free → Browse all 514 diagnosesEducational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.